anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: This study compared the masses and amounts of intramuscular non-contractile tissue of multiple lower extremity muscles measured using an ultrasound imaging device, as well as the mobility and balance ability and cognitive function between community-dwelling older adults with and without low back pain (LBP).
METHODS: Twenty-five community-dwelling older adults were classified into control (CTR) (n = 17, asymptomatic) and LBP (n = 8) groups. The current LBP status in the LBP group was as follows: duration period: 99.4 ± 81.3 months, Numerical Rating Scale: 4.8 ± 0.9, and Oswestry Disability Index: 15.3 ± 10.4%. The thicknesses and the echo intensities of various muscles (gluteus maximus, medius, and minimus; rectus femoris; vastus intermedius and lateralis; long and short heads of the biceps femoris; semitendinosus; semimembranosus; tibialis anterior; medial head of the gastrocnemius; soleus; and tibialis posterior) were measured using an ultrasound imaging device. Mobility and balance ability were assessed by measuring the usual and maximal walking speeds, timed up-and-go time, five-chair-stand time, and one-legged stance time. Mini-Mental State Examination scores were also assessed.
RESULTS: The gluteus medius muscle thickness was significantly lower in the LBP group than in the CTR group. The thicknesses and echo intensities of the other lower extremity muscles did not differ significantly between the CTR and LBP groups. The usual walking speed was also significantly slower in the LBP group than in the CTR group. Balance ability and cognitive function did not differ significantly between the two groups.
CONCLUSION: The results of the present study demonstrated lower gluteus medius muscle mass and slower usual walking speed in community-dwelling older adults with LBP compared to those in older adults without LBP; however, other variables did not differ significantly between these groups.
BACKGROUND: Phase angle (PhA), which is measured using bioelectrical impedance analysis, is an indicator of muscle quality and malnutrition. PhA has been shown to be correlated with sarcopenia and malnutrition; however, studies on patients with chronic obstructive pulmonary disease (COPD) are limited. In this study, we investigated the correlation between PhA and sarcopenia and malnutrition and determined the cutoff values of PhA for those in patients with COPD.
METHODS: This study included 105 male patients with COPD (mean age 75.7 ± 7.7 years, mean forced expiratory volume in 1s % predicted [%FEV1] 57.0 ± 20.1%) and 12 male controls (mean age 74.1 ± 3.8 years) who were outpatients between December 2019 and March 2024. PhA was measured using the InBody S10, and its correlation with sarcopenia and malnutrition was assessed. The cutoff PhA values for sarcopenia and malnutrition were determined using receiver operating characteristic curves.
RESULTS: The prevalence rates of sarcopenia and malnutrition were 31% and 22%, respectively, in patients with COPD. PhA significantly correlated with sarcopenia- and malnutrition-related indicators. Multivariate logistic regression analysis independently correlated PhA with sarcopenia and malnutrition. The cutoff values of the PhA for sarcopenia and malnutrition were 4.75° (AUC = 0.78, 95% CI = 0.68-0.88) and 4.25° (AUC = 0.75, 95% CI = 0.63-0.86), respectively.
CONCLUSIONS: PhA was significantly correlated with sarcopenia and malnutrition in Japanese patients with COPD and may be a useful diagnostic indicator.
The invention discloses osteopathic liquor used for treating fraction reduction and soft tissue injuries. The liquor is made from the raw materials with the following weight portions: 10 to 20 portions of angelica sinensis, 10 to 20 portions of red peony root, 10 to 20 portions of white peony root, 10 to 20 portions of Szechwan Lovage Rhizome, 13 to 23 portions of peach seed, 10 to 20 portions of safflower, 13 to 23 portions of india madder root, 10 to 20 portions of rhubarb, 10 to 20 portions of manyleaf paris rhizome, 10 to 20 portions of gardenia, 10 to 20 portions of frankincense, 10 to 20 portions of Myrrhe and 2100 to 2900 portions of white spirit. During the preparation, the raw material drugs are put in a vessel which is filled with white spirit to be immersed for 15 days. Then, after the residue filtering, the osteopathic liquor is obtained. The orthopedic liquor is provided with obvious effects. With the outer applying method directly acting on the affected part, fast and strong detumescence analgesic effect is provided. Especially for the fraction reduction, the blood stasis dispersing and analgesic effect is more miraculous after the reheating. Pains of patients can be relieved rapidly. Anesthetic action is substituted, no side-effect is provided, and the liquor can be called perfect osteopathic liquor.
NEW MATERIAL:The compound of formula I (R is group of formula II, formula III or formula IV). EXAMPLE:The compound of formula V. USE:An agent having antitumor activity and excellent solubility in water. PREPARATION:The objective compound can be produced by reacting a compound of formula VI with a compound of formula VII in an organic solvent (e.g. N,N-dimethylformamide) in the presence of a base (e.g. potassium carbonate) and heating the resultant compound at about 40 deg.C in an organic solvent (e.g. methanol) in the presence of an acid (e.g. dilute hydrochloric acid).
The invention belongs to the technical field of traditional Chinese medicine products, and particularly relates to a medical fungi formula for preventing and treating diabetes and a preparation method of the medical fungi formula. The medical fungi formula for preventing and treating diabetes comprises the following components in parts by weight: 20-70 parts of Inonotus obliquus, 10-50 parts of Phellinus igniarius (L. ex Fr.) Quel., 10-50 parts of Coriolous Dersicolor (Fr.) Quel and 5-50 parts of Ganoderma sinense Zhao Xu et Zhang. The invention provides the medical fungi formula for preventing and treating type-II diabetes and the preparation method of the medical fungi formula. The main ingredients of the medical fungi formula are fungi and do not harm human bodies. The medical fungi formula not only has effect of treating and preventing diabetes, but also facilitates nutrition absorption of human bodies, and has health-care effect. The medical fungi formula is suitable for being popularized and used in the fields of related products.
Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.
PURPOSE:To eliminate an oil feeling and to increase the stability of the titled emulsion by blending one or >=2 kinds of the volatile oils, a lipophilic surfactant, polyvalent alcohol having >=3 OH groups in a molecule and water. CONSTITUTION:A water in oil type emulsion is prepared by blending one or >=2 kinds of the volatile oils, the lipophilic surfactant, the polyvalent alcohol having >=3 OH groups in the molecule and water. As the volatile oil, hydrocarbon having low b.p. or silicone oil is used and the amount to be blended is preferably 5-50wt% (per water in oil type emulsion composition, and so forth). As the polyvalent alcohol having >=3 OH groups in the molecule, glycerin and arabitol, etc., are used and the amount to be blended is preferably 1-60wt%. Also as the lipophilic surfactant, polyglycerin esters are used and the amount to be blended is preferably 1-20wt%.
Patients receive diet modification coaching via telephone for 10 sessions over 30-60 minutes over 17 weeks. Patients also receive 3 motivational messages per week via email and/or text message beginning after session 6.
Episodic angioedema with eosinophilia (EAE), also known as Gleich s Syndrome,is a rare disorder characterized by recurrent episodes of urticaria, fever, angioedema, weight gain and dramatic eosinophilia that occur at 3- to 6-week intervals and resolve with spontaneous diuresis in the absence of therapy. Although the syndrome is often classified in the broad category of idiopathic hypereosinophilic syndrome (HES), EAE is a distinct eosinophilic syndrome that is remarkably homogeneous in clinical presentation. More recently, it has become apparent that there is multilineage cycling, involving lymphocytes and neutrophils in addition to eosinophils. Early studies described cyclic elevations of serum interleukin 5 (IL-5) preceding the rise in eosinophilia, and additional studies have shown cyclic elevations in other type II cytokines as well as in eosinophilic chemokines. Aberrant T cells with a CD3-CD4+ surface phenotype have also been detected in the majority of subjects with EAE. The cyclic nature of the disorder and the involvement of multiple cell lineages have made it difficult to determine the underlying cause of EAE.

We hypothesize that IL-5 driven eosinophilia is central to the pathogenesis of EAE. Suppression of eosinophil cycling by blocking IL-5 would help determine whether eosinophils are indeed the main drivers of the symptoms of angioedema and urticaria and pave the way for future mechanistic studies investigating the etiology of this unusual disorder. The purpose of this pilot study is to evaluate the effect of mepolizumab, a humanized antibody to IL-5, on eosinophil cycling in 12 subjects with EAE. Subjects with EAE will undergo screening on the National Institutes of Health protocol 94-I-0079 to establish the periodicity of their cycling (if not previously determined) and the optimal timing for the baseline visit. After screening, subjects will be followed closely with signs and symptoms recorded in a daily log and daily and monthly questionnaires, as well as complete blood counts and research blood collected for one cycle prior to administration of mepolizumab. Subjects will receive a total of 3 monthly administrations of mepolizumab at 700 mg, followed by drug de-escalation over 6 additional monthly administrations for subjects who demonstrate benefit from mepolizumab. All subjects will have a follow-up visit about 1 month after the last study administration of mepolizumab.

The primary efficacy endpoint will be reduction of symptoms and severity of symptoms after mepolizumab. Secondary endpoints will include reduction in peak eosinophils after mepolizumab, continued suppression of absolute eosinophil count and reduction in symptoms following monthly dosing of mepolizumab therapy.
First, a multicenter, double-blind, randomized control study is going to be carried out. 60 recruited patients will be randomized assigned to the intervention group (40) and the control group (20), receiving either 4-week of repetitive transcranial magnetic stimulation (rTMS) treatment or 4-week of sham rTMS treatment. Both groups will receive 16-week urine drug test (1 time per week, 4 weeks before rTMS, 4 weeks during rTMS and 8 weeks after rTMS). Self-report methamphetamine use or urine test is set as primary outcome. Cognitive function and craving are also evaluated before and after the intervention. Functional magnetic resonance imaging (fMRI) is applied to investigate the potential neurobiological mechanism of rTMS treatment. This study will be very helpful to develop an evidence-based rTMS treatment protocols for methadone maintenance therapy with methamphetamine abuse and decrease risk of relapse for both the patients and their families.
Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
The flexible pipe for inserting endoscope into duodenum, small- and large intestine to examine gastro-intestinal tract, has flexible tubing section (3) and bendable section (4), whose proximal end is coupled with the distal end of the flexible tubing section. The tubing section has a first core element (31) and a first outer envelope (32), which covers the first core element. The bendable section has a second core element and a second outer envelope, which covers the second core element. The first envelope consists of a material in its exterior surface and in an area near to the exterior surface. The flexible pipe for inserting endoscope into duodenum, small- and large intestine to examine gastro-intestinal tract, has flexible tubing section (3) and bendable section (4), whose proximal end is coupled with the distal end of the flexible tubing section. The tubing section has a first core element (31) and a first outer envelope (32), which covers the first core element. The bendable section has a second core element and a second outer envelope, which covers the second core element. A clamping cord (9) is intended, with which the exterior surfaces of the distal end section of the first envelope and the proximal end section of the second envelope are wrapped. The first envelope consists of a material in its exterior surface and in an area near to the exterior surface. The material exhibits a relatively weak adhesive strength in relation to the adhesive, and the area covered by the adhesive of the first envelope is pretreated with a pre-treatment agent in such a way that the adhesive strength of the first envelope is strengthened in relation to the adhesive. During the pretreatment, the pretreatment agent penetrates into the first envelope with pre-determined penetration depth. The pre-determined depth is more than 30% of the thickness of the first envelope. The exterior surface of the first envelope is modified by the pretreatment. An independent claim is included for an endoscope equipped with flexible pipe.
The course of an ischemic stroke varies by many factors. The influence of periodontal diseases and the stimulation of salivation on the course and difficulty of stroke remains unresolved.

Methods: 100 consecutive patients with their first ever ischemic stroke were enrolled in the study. 56 randomly selected patients were subjected to stimulation of salivation, the remaining patients were not stimulated. The severity of the neurological condition was assessed using the NIHSS scale on days 1, 3 and 7 of stroke. The incidence of periodontal diseases was classified using the Hall's scale in the 1st day of stroke. On days 1 and 7 of stroke, the concentration of IL-1beta, MMP8, OPG and RANKL in the patients' saliva was assessed using the Elisa technique. At the same time, the level of CRP and the number of leukocytes in the peripheral blood were tested on days 1, 3 and 7 of the stroke, and the incidence of upper respiratory and urinary tract infections was assessed.
Endometriosis is one of the most common causes of chronic pelvic pain and infertility that affects 10% of women of reproductive age. It is currently defined as the presence of endometrial epithelial and stromal cells at ectopic sites; however, advances in endometriosis research have some authors believing that endometriosis should be re-defined as "a fibrotic condition in which endometrial stroma and epithelium can be identified". microRNAs (miRNAs) are regulatory molecules that potentially play a role in endometriotic lesion development. There is evidence that suggests that miRNAs, including microRNA-21 (miR-21), participate in fibrotic processes in different organs, including the heart, kidney, liver and lungs. The objective of this study was to understand the role of miR-21 and the mechanisms that can contribute to the development of fibrosis by determining how IL-6 regulates miR-21 expression and how this miRNA regulates the transforming growth factor beta (TGF-β) signaling pathway to promote fibrosis. We investigated the expression of miR-21 in the baboon and mouse model of endometriosis and its correlation with fibrosis. We demonstrated that inflammation and fibrosis are present at a very early stage of endometriosis and that the inflammatory environment in the peritoneal cavity, which includes interleukin 6 (IL-6), can regulate the expression of miR-21 in vitro and in vivo.
Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
In the randomized trial, 2% of patients on the Xofigo arm experienced bone marrow failure or ongoing pancytopenia compared to no patients treated with placebo. There were two deaths due to bone marrow failure and for 7 of 13 patients treated with Xofigo, bone marrow failure was ongoing at the time of death. Among the 13 patients who experienced bone marrow failure, 54% required blood transfusions. Four percent (4%) of patients on the Xofigo arm and 2% on the placebo arm permanently discontinued therapy due to bone marrow suppression. 

In the randomized trial, deaths related to vascular hemorrhage in association with myelosuppression were observed in 1% of Xofigo-treated patients compared to 0.3% of patients treated with placebo. The incidence of infection-related deaths (2%), serious infections (10%), and febrile neutropenia (<1%) were similar for patients treated with Xofigo and placebo. Myelosuppression; notably thrombocytopenia, neutropenia, pancytopenia, and leukopenia; has been reported in patients treated with Xofigo. In the randomized trial, complete blood counts (CBCs) were obtained every 4 weeks prior to each dose and the nadir CBCs and times of recovery were not well characterized. In a separate single-dose phase 1 study of Xofigo, neutrophil and platelet count nadirs occurred 2 to 3 weeks after Xofigo administration at doses that were up to 1 to 5 times the recommended dose, and most patients recovered approximately 6 to 8 weeks after administration [see Adverse Reactions (6)]. 

Hematologic evaluation of patients must be performed at baseline and prior to every dose of Xofigo. Before the first administration of Xofigo, the absolute neutrophil count (ANC) should be ≥ 1.5 x 109/L, the platelet count ≥ 100 x 109/L and hemoglobin ≥ 10 g/dL. Before subsequent administrations of Xofigo, the ANC should be ≥ 1 x 109/L and the platelet count ≥ 50 x 109/L. If there is no recovery to these values within 6 to 8 weeks after the last administration of Xofigo, despite receiving supportive care, further treatment with Xofigo should be discontinued. Patients with evidence of compromised bone marrow reserve should be monitored closely and provided with supportive care measures when clinically indicated. Discontinue Xofigo in patients who experience life-threatening complications despite supportive care for bone marrow failure.

The safety and efficacy of concomitant chemotherapy with Xofigo have not been established. Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression. If chemotherapy, other systemic radioisotopes or hemibody external radiotherapy are administered during the treatment period, Xofigo should be discontinued.
The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
I. Vasospastic Angina

Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers.

II. Chronic Stable Angina (Classical Effort-Associated Angina)

Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and betablocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See WARNINGS).
PROBLEM TO BE SOLVED: To perform commodity management in packaging containers in a short time without requiring communication charges or communication time and do such work at low cost without requiring infrastructure arrangement. SOLUTION: A reader writer 16 is used to read commodity information one by one out of individual information tags 14a-14f pasted on the upper face of medicines 12a-12f in storing the medicines 12a-12f in a medicine box 18 from a void arrow-mark X direction. The reader writer 16 is used to write commodity information for the medicines 12a-12f on each of block information tags 20a, 20b pasted on open/closed doors 18a, 18b for the medicine box 18. In this case, time histories are also written together with the open/closed condition of the open/closed doors. The commodity information for contents can be obtained simply by making the reader writer 16 close to the block information tags 20 for the medicine box 18.  Thus, on-line commodity management is available and defects, if found on the way, are easily discriminated by comparison with the histories of the commodity information written on the block information tags 20.
Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.